News|Articles|May 30, 2024

New Psychedelic CPT Codes: Paving the Way for a New Age of Psychiatric Care

The new psychedelic CPT codes, effective January 1, 2024, could impact MDMA if approved. The FDA's Psychopharmacologic Drugs Advisory Committee will discuss MDMA on June 4.

On June 4, the US Food and Drug Administration’s Psychopharmacologic Drugs Advisory Committee will host a meeting that could bring the US closer to a new age in the management of psychiatric illnesses, with the committee preparing to discuss an application from Lykos Therapeutics for midomafetamine (MDMA) capsules in management of post-traumatic stress disorder (PTSD).^1,2

Related to this article

September 22nd, 2026

Q&A: Woolley on UMBRAA's Multidrug Approach to Psilocybin Trial Masking

Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.

September 22nd, 2026

Skin of Color Savvy: How SOCS Serves Builds Dermatology Pathways and Community Trust

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

Diane Young, MD | Image credit: LinkedIn

September 22nd, 2026

EMBARQ-CSU: Barzolvolimab Meets Primary, Secondary Endpoints in CSU Trials

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

September 22nd, 2026

FDA Updates Sotatercept Label with HYPERION Data in Early PAH

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

September 21st, 2026

Q&A: Zasocitinib Response in the Scalp, Nails, Palms and Soles

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

September 21st, 2026

PAH Experts Discuss Trial-to-Clinic Mismatch in Care

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

September 21st, 2026

FAQ: What the Expanded Marstacimab Approval Means for Hemophilia A, B

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

September 21st, 2026

Binge Drinking and ALD, MetALD Fibrosis Risk, With Frances Lee, MD

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.